Nicolas Boissel

1 month ago | nature.com | Bijal Shah |Ryan D. Cassaday |Jae Park |Nicolas Boissel |Yi Lin |Gary Schiller | +5 more

AbstractBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the US to treat adults aged ≥18 years (≥26 years in the EU) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Brexu-cel showed an overall complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate of 73% (CR rate 60%) and median overall survival (OS) of 25.4 months in 78 patients with R/R B-ALL after 2 years in ZUMA-3.

Jan 8, 2025 | nature.com | Remy Duléry |Vincent Guiraud |Sylvain Choquet |Catherine Thieblemont |Emmanuel Bachy |Stéphane Barete | +3 more

AbstractThe risk of T cell malignancies after chimeric antigen receptor (CAR) T cell therapy is a concern, although the true incidence remains unclear. Here we analyzed the DESCAR-T registry database, encompassing all pediatric and adult patients with hematologic malignancies who received CAR T cell therapy in France since 1 July 2018.